The results of the clinical trial program were published in medRxiv on September 23 and showed partial remission in 4 of 15 patients after receiving the one-month treatment, and complete remission in two patients after three months of treatment. Importantly, there were no serious adverse effects related to the CAR T therapy. The company is currently evaluating this CAR T product in several other clinical trials.

Comparison of pre- and post-treatment imaging. Image courtesy of Bioray Laboratories.

The company developed the PD1 specific targeted CD19-CART using its Quikin CART platform, which precisely inserts CAR cassette into PD1 locus without using a virus. The product combines PD1 immune checkpoint inhibition with CART anti-tumor activity to generate both anti-PD1 immunotherapy and CAR T therapy. Other advantages of Quikin technology include a simpler process, fewer production links, shorter preparation times, and higher product uniformity.

In addition to evaluating the nonviral targeting CART products for lymphoma, Bioray Laboratories is conducting research using the product for the treatment of solid tumors.

City of Hope licenses CAR T therapy to Chimeric Therapeutics
City of Hope has licensed intellectual property for its chlorotoxin chimeric antigen receptor (CAR) T-cell therapy to Chimeric Therapeutics.

Elicio, Moffitt to study combination CAR T therapy
Elicio Therapeutics and the Moffitt Cancer Center have established a collaboration to study Elicio's amphiphile immunotherapies with CD19 chimeric antigen...

Yufan, Abound Bio to develop CAR T cell therapies
Yufan Biotechnologies and Abound Bio have signed a multiyear agreement to find antibodies to direct chimeric antigen receptor (CAR) T cells against cancer...

Atara advances CAR T technology with IND clearance
Atara Biotherapeutics said that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for ATA2271, a...